🇺🇸 FDA

Company profile · Sponsor

Zealand

Zealand Pharma A/S

ED61F8E · EMA pharma EU
Pipeline
11
Drugs
0
Patents
0

Quick answer

Zealand (ED61F8E) is a pharma company. headquartered in EU. listed on EMA. NovaPharmaNews links 11 pipeline programs, 0 drugs, and 0 patents to this profile..

Company facts

Ticker ED61F8E
Exchange EMA
Company type pharma
Headquarters EU

Pipeline (11)

Search pipeline →

  1. Dasiglucagon 4 mg/ml

    Zealand

    Children with congenital hyperinsulinism

    phase 3 small molecule active

    1 trial

  2. Glepaglutide 20.0 mg/mL

    Zealand

    Short bowel syndrome

    phase 3 small molecule active

    1 trial

  3. Glepaglutide 20.0 mg/mL

    Zealand

    Short Bowel Syndrome

    phase 3 small molecule active

    1 trial

  4. Glepaglutide 20.0 mg/mL, Glepaglutide Placebo

    Zealand

    Short Bowel Syndrome

    phase 3 small molecule active

    1 trial

  5. Placebo for glepaglutide, Glepaglutide 20.0 mg/mL

    Zealand

    Short Bowel Syndrome

    phase 3 small molecule active

    1 trial

  6. Placebo for petrelintide, Petrelintide, Petrelintide

    Zealand

    Weight management

    phase 2 small molecule active

    1 trial

  7. A Trial Comparing Pharmacokinetics, Safety and Tolerability of Two Subcutaneous Concentrations of Dapiglutide

    Zealand

    Weight management

    phase 1 other active

    1 trial

  8. A clinical research study investigating how the body processes the new compound petrelintide in people with kidney problems

    Zealand

    Weight management

    phase 1 other active

    1 trial

  9. Investigating the pharmacokinetics of petrelintide using different drug product concentrations in participants with a BMI ≥27.0 kg/m2

    Zealand

    Weight reduction

    phase 1 other active

    1 trial

  10. PHARMACOKINETICS OF PETRELINTIDE FOLLOWING ADMINISTRATION TO PARTICIPANTS WITH IMPAIRED HEPATIC FUNCTION

    Zealand

    Healthy / hepatic impaired volunteers only study to assess PK parameters

    phase 1 other active

    1 trial

  11. Single and multiple ascending dose of ZP9830 in healthy participants

    Zealand

    Autoimmune diseases

    phase 1 other active

    1 trial

Frequently asked questions

What is Zealand?

Zealand (ED61F8E) is a pharma company. headquartered in EU. listed on EMA. NovaPharmaNews links 11 pipeline programs, 0 drugs, and 0 patents to this profile..

What pipeline programs does Zealand sponsor?

We track 11 ClinicalTrials.gov-linked programs for Zealand, including Dasiglucagon 4 mg/ml and 10 more. Open each program for phase, modality, NCT IDs, and indication details.

Where does Zealand company data come from?

Profiles combine SEC EDGAR (CIK/ticker), ClinicalTrials.gov sponsor links, FDA drug records, and USPTO patent metadata. See our data sources page. This profile is for professional reference, not investment advice.